ArticleMolecules and cells2016
Baicalein Inhibits Epithelial to Mesenchymal Transition via Downregulation of Cyr61 and LOXL-2 in MDA-MB231 Breast Cancer Cells.
Article in Molecules and cells, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It has been retracted, and should not be counted. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed.
- Anti-metastatic potential of flavonoids for the treatment of cancers: focus on epithelial-mesenchymal transition (EMT) process.Naunyn-Schmiedeberg's archives of pharmacology · 2025Review
- Baicalein blocked gastric cancer cell proliferation and invasion through modulated platelet type 12-lipoxygenase.Iranian journal of basic medical sciences · 2024Article
- Anti-Cancer Potential of Phytochemicals: The Regulation of the Epithelial-Mesenchymal Transition.Molecules (Basel, Switzerland) · 2023Review
- CYR61 promotes colorectal carcinoma progression via activating epithelial-mesenchymal transition.American journal of cancer research · 2023Article
- The interaction between cucurbit[8]uril and baicalein and the effect on baicalein properties.Beilstein journal of organic chemistry · 2020Article
- Honokiol inhibits breast cancer cell metastasis by blocking EMT through modulation of Snail/Slug protein translation.Acta pharmacologica Sinica · 2019Article
- Controlling metastatic cancer: the role of phytochemicals in cell signaling.Journal of cancer research and clinical oncology · 2019Review
- USP5 promotes epithelial-mesenchymal transition by stabilizing SLUG in hepatocellular carcinoma.Theranostics · 2019Article
- Polymorphisms of the CYR61 gene in patients with acute myeloid leukemia in a Han Chinese population.Medicine · 2018Article
- Baicalein suppresses non small cell lung cancer cell proliferation, invasion and Notch signaling pathway.Cancer biomarkers : section A of Disease markers · 2018Article
- Lysyl Oxidase-like Protein LOXL2 Promotes Lung Metastasis of Breast Cancer.Cancer research · 2017Article
- Inhibition of Increased Invasiveness of Breast Cancer Cells With Acquired Tamoxifen Resistance by Suppression of CYR61.Cancer genomics & proteomicsArticle
Corrections and comments
- Retraction · 2019-04-30Duplication of Data · Falsification/Fabrication of Data ·
- Retracted
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Epithelial-mesenchymal transition (EMT) is a critical step in the acquisition of the migratory and invasive capabilities associated with metastatic competence. Cysteine-rich protein 61 (CCN1/Cyr61) has been implicated as an important mediator in the proliferation and metastasis of breast cancer. Hence, Cyr61 and associated pathways are attractive targets for therapeutic interventions directed against the EMT. In the present study, we report that baicalein significantly inhibits the expression of Cyr61 and migration and invasion of MDA-MB231 human breast cancer cells. Exposure to baicalein led to increased E-cadherin expression, possibly due to the ubiquitination of Snail and Slug, which was mediated by the Cyr61/Akt/glycogen synthase kinase 3β (GSK3β) pathway. Further analysis revealed that baicalein inhibited the expression of lysyl oxidase like-2 (LOXL-2), which is a functional collaborator of Snail and Slug, and subsequently attenuated the direct interaction between LOXL-2 and Snail or Slug, thereby enhancing GSK3β-dependent Snail and Slug degradation. Our findings provide new insights into the antimetastatic mechanism of baicalein and may contribute to its beneficial use in breast cancer therapies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.